(ANIP) ANI Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00182C1036

ANIP: Tablets, Capsules, Liquids, Topicals, Powders, Injectables

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) stands as a biopharmaceutical entity specializing in the development, manufacturing, and distribution of both branded and generic prescription medications across the U.S. and Canada. Their operational backbone includes a diverse manufacturing portfolio, encompassing oral solids, semi-solids, liquids, topicals, controlled substances, and potent products, alongside contract development and manufacturing services.

The companys distribution network is extensive, reaching retail pharmacies, wholesalers, distributors, mail-order services, group purchasing organizations, specialty pharmacies, and hospitals. This broad access ensures their products are widely available, catering to various market segments and patient needs.

Founded in 2001 and headquartered in Baudette, Minnesota, ANI Pharmaceuticals has established a robust presence in the pharmaceutical industry. Their strategic focus on both branded and generic drugs allows them to capitalize on different revenue streams, balancing the stability of generics with the higher margins of branded products.

Financially, ANI Pharmaceuticals presents a market cap of $1.238 billion, with a forward P/E of 9.51, indicating expectations for growth. Their P/S ratio of 2.23 reflects a reasonable valuation relative to their revenue, suggesting operational efficiency. A P/B ratio of 3.05 points to a premium on book value, possibly due to intangible assets or growth prospects.

Investors and fund managers may find ANI Pharmaceuticals appealing due to their diversified product portfolio and established manufacturing capabilities. Their focus on niche markets and complex formulations positions them strategically in a competitive landscape, offering a balance of stability and growth potential.

As the pharmaceutical industry evolves, ANIs ability to adapt and innovate will be crucial. Their emphasis on a strong product pipeline and strategic manufacturing investments positions them well to navigate future challenges and capitalize on emerging opportunities.

Additional Sources for ANIP Stock

ANIP Stock Overview

Market Cap in USD 1,360m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2000-05-05

ANIP Stock Ratings

Growth 5y 36.3%
Fundamental 11.5%
Dividend 0.0%
Rel. Strength Industry -6.22
Analysts 4.17/5
Fair Price Momentum 62.97 USD
Fair Price DCF 49.97 USD

ANIP Dividends

No Dividends Paid

ANIP Growth Ratios

Growth Correlation 3m 67.4%
Growth Correlation 12m -76.9%
Growth Correlation 5y 81.4%
CAGR 5y 15.51%
CAGR/Max DD 5y 0.26
Sharpe Ratio 12m -0.61
Alpha -13.42
Beta 0.59
Volatility 48.22%
Current Volume 199.3k
Average Volume 20d 259.5k
What is the price of ANIP stocks?
As of March 15, 2025, the stock is trading at USD 62.49 with a total of 199,309 shares traded.
Over the past week, the price has changed by +3.08%, over one month by +6.06%, over three months by +10.88% and over the past year by -5.39%.
Is ANI Pharmaceuticals a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, ANI Pharmaceuticals is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 11.45 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ANIP as of March 2025 is 62.97. This means that ANIP is currently overvalued and has a potential downside of 0.77%.
Is ANIP a buy, sell or hold?
ANI Pharmaceuticals has received a consensus analysts rating of 4.17. Therefor, it is recommend to buy ANIP.
  • Strong Buy: 2
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ANIP stock price target?
According to ValueRays Forecast Model, ANIP ANI Pharmaceuticals will be worth about 68.1 in March 2026. The stock is currently trading at 62.49. This means that the stock has a potential upside of +8.96%.
Issuer Forecast Upside
Wallstreet Target Price 81.5 30.4%
Analysts Target Price 78.7 25.9%
ValueRay Target Price 68.1 9%